<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04745624</url>
  </required_header>
  <id_info>
    <org_study_id>2000028947</org_study_id>
    <nct_id>NCT04745624</nct_id>
  </id_info>
  <brief_title>Real World Use and Outcomes of VASCADE Closure Device Versus Manual Compression in Patients With CFA Disease</brief_title>
  <acronym>VASCADE</acronym>
  <official_title>Real World Use and Outcomes of VASCADE Closure Device Versus Manual Compression in Patients With Common Femoral Artery Disease: A Retrospective Comparison Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the patient characteristics and outcomes associated with the real-world use of&#xD;
      manual compression vs. vascular closure devices (VCDs) after common femoral artery (CFA)&#xD;
      percutaneous access for coronary and endovascular interventions. An institutional procedural&#xD;
      database, based on electronic medical record information will be abstracted to collect this&#xD;
      information.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall objective of the study will be to examine the safety and efficacy of the VASCADE&#xD;
      closure device compared to manual compression (standard of care) to achieve hemostasis after&#xD;
      endovascular procedures requiring access within a severely diseased CFA.&#xD;
&#xD;
      This study will be a retrospective single center review of 200 patients undergoing&#xD;
      endovascular procedures utilizing vascular access within a severely diseased CFA between 2018&#xD;
      and 2020 at Yale New Haven Hospital. A random selection of patients undergoing hemostasis&#xD;
      with manual compression (n = 100) and VASCADE vascular closure system (n = 100) will be&#xD;
      conducted. The two groups will then be statistically compared with respect to 48-hour and&#xD;
      30-day safety and efficacy outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 20, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adequate hemostasis - (efficacy)</measure>
    <time_frame>within an hour immediately after procedure</time_frame>
    <description>No evidence of bleeding after device use</description>
  </primary_outcome>
  <primary_outcome>
    <measure>No complications after procedure - (safety)</measure>
    <time_frame>early (48 hours)</time_frame>
    <description>Early complications rates: bleeding, thrombosis, pseudoaneurysm, arterio-venous fistula, access site infection, mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>No complications after procedure - (safety)</measure>
    <time_frame>late (30-day)</time_frame>
    <description>Late complications rates: bleeding, thrombosis, pseudoaneurysm, arterio-venous fistula, access site infection, mortality</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Common Femoral Artery Stenosis</condition>
  <arm_group>
    <arm_group_label>manual compression cohort</arm_group_label>
    <description>Manual compression cohort: Patients who underwent coronary or peripheral angiograms via CFA access with moderate to severe stenosis were hemostasis was achieved via manual compression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VASCADE cohort</arm_group_label>
    <description>VASCADE cohort: Patients who underwent coronary or peripheral angiograms via CFA access with moderate to severe stenosis were hemostasis was achieved via VASCADE device closure</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        This will be a retrospective review of medical records and angiograms of patients who&#xD;
        underwent coronary and peripheral angiograms at one institution. Patients with CFA stenosis&#xD;
        will be identified by review of their access site angiograms. The method use for&#xD;
        hemostasis, characteristics and outcomes will be abstracted via review of medical records.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 5, 6 or 7 Fr access within the CFA&#xD;
&#xD;
          2. ACT &lt; 300 seconds&#xD;
&#xD;
          3. Age 18 - 90 years old&#xD;
&#xD;
          4. Severe common femoral arterial disease Percent stenosis &gt; 50, which will be core-lab&#xD;
             adjudicated&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Ipsilateral CFA access within 30 days preceding or subsequent to the index case&#xD;
&#xD;
          2. Prior ipsilateral closure device use, other than VASCADE&#xD;
&#xD;
          3. High bleeding risk ACT &gt; 300 or &gt; 250 with IIb/IIIa inhibitor Plt &lt; 50K INR &gt; 1.7 on&#xD;
             the day of procedure Inherent coagulopathy NOAC, warfarin, or lovenox administered&#xD;
             within 24 hours of the procedure&#xD;
&#xD;
          4. Suspected intraluminal thrombus, dissection, pseudoaneurysm, hematoma, or AV Fistula&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Carlos Mena-Hurtado, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kim Smolderen</last_name>
    <role>Study Director</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bangalore S, Bhatt DL. Femoral arterial access and closure. Circulation. 2011 Aug 2;124(5):e147-56. doi: 10.1161/CIRCULATIONAHA.111.032235.</citation>
    <PMID>21810667</PMID>
  </reference>
  <reference>
    <citation>Noori VJ, Eldrup-JÃ¸rgensen J. A systematic review of vascular closure devices for femoral artery puncture sites. J Vasc Surg. 2018 Sep;68(3):887-899. doi: 10.1016/j.jvs.2018.05.019. Epub 2018 Jun 29. Review.</citation>
    <PMID>30146036</PMID>
  </reference>
  <reference>
    <citation>Arora N, Matheny ME, Sepke C, Resnic FS. A propensity analysis of the risk of vascular complications after cardiac catheterization procedures with the use of vascular closure devices. Am Heart J. 2007 Apr;153(4):606-11.</citation>
    <PMID>17383300</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 4, 2021</study_first_submitted>
  <study_first_submitted_qc>February 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2021</study_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

